UNSPSC 51331707: Sultopride hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C17H26N2O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Q6926T32J, chemically known as n-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride, but more generally known as sultopride hydrochloride, which bears US NIH Compound Identifier 41485. European Medicines Agency schedules sultopride hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10763MIG.

Most nations, for tariff purposes, schedule sultopride hydrochloride under HS 29339990. SMILES: CCN1CCCC1CNC(=O)C2CC(CCC2OC)S(=O)(=O)CC.CL.

UNSPSC 51331707 Sultopride hydrochloride is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local activity under this code shows minimal direct alignment with the abstract product name. The recent opportunities posted under this code span naloxone procurement, therapeutic pharmacy initiatives involving direct-to-manufacturer contracts, and generic multi-source pharmaceutical supply agreements—none of which reference sultopride hydrochloride explicitly. State and local health departments, cooperative purchasing alliances, and human services commissions are the primary issuing bodies soliciting pharmaceutical products and services under this taxonomy, typically seeking annual supplies of medications, OTC products, and related health delivery systems through competitive bidding and RFP processes. The solicitations show that governments are buying pharmaceutical supply agreements with negotiated pricing, direct-to-manufacturer relationship capability, and authorized wholesaler distribution networks rather than single active ingredients in isolation.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription programs before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, and contract effectiveness targeted for July 1, 2026. The mismatch between the code's nominal scope (sultopride hydrochloride) and the actual procurement activity suggests this code may be misapplied in state and local systems or that recent opportunities have been tagged incorrectly; the code shows little relevant recent activity aligned with its stated pharmaceutical product.